Philips Q2 2026: 4% Sales Growth, Margin Boost from US Tariff Refund, Raised Full-Year Outlook
PHG is trading near its 52-week low of $24.82 (3.9% below the low) on elevated volume (5.1× avg).
Summary
Philips reported Q2 comparable sales growth of 4% and raised its full-year margin and cash flow outlook, driven by a US tariff refund. Underlying margins were flat as inflation and tariffs offset sales gains.
Key Events · Earnings and Guidance · PHG
-
Q2 Sales Growth of 4%
Group sales reached EUR 4.4 billion, with comparable growth of 4% driven by all segments: Diagnosis & Treatment +2%, Connected Care +2%, Personal Health +8%.
-
US Tariff Refund Boosts Margins
A EUR 186 million US tariff refund lifted Adjusted EBITA margin to 16.4% (vs. 12.4% in Q2 2025). Excluding the refund, margin was roughly flat as cost inflation and tariffs offset higher sales and productivity.
-
Full-Year Guidance Raised
2026 Adjusted EBITA margin outlook increased to 13.5%-14.0% (from 12.5%-13.0%) and free cash flow to EUR 1.5-1.7 billion (from EUR 1.3-1.5 billion), reflecting the tariff refund benefit. Comparable sales growth outlook reiterated at 3%-4.5%.
-
Divestiture Gain of EUR 99 Million
A gain on the sale of a divested business contributed EUR 99 million, recorded in Connected Care restructuring and acquisition-related items.
Analysis · PHG · Industrial Applications And Services
Philips delivered solid Q2 results with 4% comparable sales growth across all segments and a significant margin boost from a EUR 186 million US tariff refund. Excluding the one-time refund, underlying profitability was pressured by cost inflation and higher tariffs, but the company raised its full-year Adjusted EBITA margin and free cash flow guidance. The update also includes a EUR 99 million gain from a divestiture and progress on Respironics legal matters, providing a clearer picture of operational momentum and ongoing risks.
At the time of this filing, PHG was trading at $23.84 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $26B. The 52-week trading range was $24.82 to $33.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.